PE20000011A1 - Combinacion eficaz para el tratamiento de la impotencia - Google Patents
Combinacion eficaz para el tratamiento de la impotenciaInfo
- Publication number
- PE20000011A1 PE20000011A1 PE1998001206A PE00120698A PE20000011A1 PE 20000011 A1 PE20000011 A1 PE 20000011A1 PE 1998001206 A PE1998001206 A PE 1998001206A PE 00120698 A PE00120698 A PE 00120698A PE 20000011 A1 PE20000011 A1 PE 20000011A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- impotence
- treatment
- compound
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE a)UN ANTAGONISTA DEL RECEPTOR ALFA-ADRENERGICO SIENDO DE PREFERENCIA MESILATO DE DOXAZOCIN, TERAZOSIN, ABANOQUILO, PRAZOSIN, ALFUZOSIN, INDORAMIN, NAFTOPIDILO, FENTOLAMINA, TAMSULOSIN, TRAZODONA, DAPIPRAZOL, FENOXIBENZAMINA, IDAZOXAN, EFAROXAN, YOHIMBINA; b)UN COMPUESTO QUE ELEVA LOS NIVELES DE LA GUANOSIN 3`,5'-MONOFOSFATO CICLICO (cGMP) AL INHIBIR A LA FOSFODIESTERASA (cGMP PDEv) TAL COMO SILDENAFIL O UN COMPUESTO DE FORMULA I, DONDE R (CERO) ES H, HALOGENO, ALQUILO C1-C6; R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, HALO, ALQUILO C1-C6, CICLOALQUILO C3-C8, ENTRE OTROS; R2 ES UN ANILLO AROMATICO MONOCICLICO OPCIONALMENTE SUSTITUIDO, UN ANILLO BICICLICO; R3 ES H, ALQUILO C1-C3; O R1 Y R3 SON JUNTOS ALQUILO, ALQUENILO DE 3 A 4 MIEMBROS. LA COMPOSICION TIENE EFECTO SINERGICO PARA EL TRATAMIENTO DE LA IMPOTENCIA, DISFUNCION ERECTIL, DISFUNCION SEXUAL FEMENINA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6974197P | 1997-12-16 | 1997-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20000011A1 true PE20000011A1 (es) | 2000-01-18 |
Family
ID=22090927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1998001206A PE20000011A1 (es) | 1997-12-16 | 1998-12-11 | Combinacion eficaz para el tratamiento de la impotencia |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP1037616B1 (es) |
JP (2) | JP2002508315A (es) |
KR (1) | KR20010033092A (es) |
CN (1) | CN1282248A (es) |
AP (1) | AP915A (es) |
AR (1) | AR016433A1 (es) |
AT (1) | ATE318602T1 (es) |
AU (1) | AU759825B2 (es) |
BG (1) | BG104528A (es) |
BR (1) | BR9813699A (es) |
CA (1) | CA2314993A1 (es) |
CO (1) | CO4810381A1 (es) |
CZ (1) | CZ20002199A3 (es) |
DE (1) | DE69833671T2 (es) |
DZ (1) | DZ2675A1 (es) |
EA (1) | EA200000526A1 (es) |
ES (1) | ES2258300T3 (es) |
GT (1) | GT199800177A (es) |
HN (1) | HN1998000174A (es) |
HR (1) | HRP20000407A2 (es) |
HU (1) | HUP0100705A3 (es) |
IL (1) | IL136515A0 (es) |
IS (1) | IS5504A (es) |
MA (1) | MA26586A1 (es) |
NO (1) | NO20003065L (es) |
NZ (1) | NZ504487A (es) |
OA (1) | OA11423A (es) |
PA (1) | PA8462801A1 (es) |
PE (1) | PE20000011A1 (es) |
PL (1) | PL341575A1 (es) |
SK (1) | SK8782000A3 (es) |
TN (1) | TNSN98227A1 (es) |
TR (1) | TR200001733T2 (es) |
UY (1) | UY25300A1 (es) |
WO (1) | WO1999030697A2 (es) |
YU (1) | YU33700A (es) |
ZA (1) | ZA9811507B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
DE19844162A1 (de) * | 1998-09-25 | 2000-03-30 | Udo Dunzendorfer | Medikamentenkombinationen zur Therapie der erektilen Dysfunktion |
WO2000053148A2 (en) * | 1999-03-08 | 2000-09-14 | Merck & Co., Inc. | Methods and compositions for treating erectile dysfunction |
US7235625B2 (en) * | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
ES2435816T3 (es) * | 1999-08-03 | 2013-12-23 | Icos Corporation | Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
WO2002022127A1 (en) * | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
EP1333824B1 (en) * | 2000-11-17 | 2005-09-07 | Warner-Lambert Company LLC | Treatment of sexual dysfunction with bombesin receptor antagonists |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
US8293489B2 (en) | 2007-01-31 | 2012-10-23 | Henkin Robert I | Methods for detection of biological substances |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
CN101781302B (zh) * | 2009-05-31 | 2013-07-10 | 段波 | 一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用 |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
EP2903619B1 (en) | 2012-10-05 | 2019-06-05 | Robert I. Henkin | Phosphodiesterase inhibitors for treating taste and smell disorders |
CN106233141B (zh) | 2014-02-18 | 2018-08-21 | 罗伯特·I·汉金 | 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA878182B (en) * | 1986-11-05 | 1988-05-02 | Merrell Dow Pharmaceuticals Inc. | Enhancement of prazosin |
FR2649613B1 (fr) * | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
DE69105040T2 (de) * | 1990-05-31 | 1995-03-23 | Pfizer, Inc., New York, N.Y. | Arzneimittel gegen Impotenz. |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9523752D0 (en) * | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
-
1998
- 1998-10-29 HU HU0100705A patent/HUP0100705A3/hu unknown
- 1998-10-29 AT AT98947741T patent/ATE318602T1/de not_active IP Right Cessation
- 1998-10-29 YU YU33700A patent/YU33700A/sh unknown
- 1998-10-29 EA EA200000526A patent/EA200000526A1/ru unknown
- 1998-10-29 CZ CZ20002199A patent/CZ20002199A3/cs unknown
- 1998-10-29 SK SK878-2000A patent/SK8782000A3/sk unknown
- 1998-10-29 JP JP2000538680A patent/JP2002508315A/ja active Pending
- 1998-10-29 EP EP98947741A patent/EP1037616B1/en not_active Revoked
- 1998-10-29 TR TR2000/01733T patent/TR200001733T2/xx unknown
- 1998-10-29 ES ES98947741T patent/ES2258300T3/es not_active Expired - Lifetime
- 1998-10-29 NZ NZ504487A patent/NZ504487A/xx unknown
- 1998-10-29 DE DE69833671T patent/DE69833671T2/de not_active Expired - Fee Related
- 1998-10-29 CA CA002314993A patent/CA2314993A1/en not_active Abandoned
- 1998-10-29 IL IL13651598A patent/IL136515A0/xx unknown
- 1998-10-29 PL PL98341575A patent/PL341575A1/xx unknown
- 1998-10-29 AU AU94558/98A patent/AU759825B2/en not_active Ceased
- 1998-10-29 CN CN98812331A patent/CN1282248A/zh active Pending
- 1998-10-29 WO PCT/IB1998/001723 patent/WO1999030697A2/en active IP Right Grant
- 1998-10-29 KR KR1020007006455A patent/KR20010033092A/ko not_active Application Discontinuation
- 1998-10-29 BR BR9813699-2A patent/BR9813699A/pt not_active Application Discontinuation
- 1998-11-09 GT GT199800177A patent/GT199800177A/es unknown
- 1998-11-10 PA PA19988462801A patent/PA8462801A1/es unknown
- 1998-11-11 HN HN1998000174A patent/HN1998000174A/es unknown
- 1998-11-30 CO CO98070722A patent/CO4810381A1/es unknown
- 1998-12-10 AP APAP/P/1998/001414A patent/AP915A/en active
- 1998-12-11 PE PE1998001206A patent/PE20000011A1/es not_active Application Discontinuation
- 1998-12-14 UY UY25300A patent/UY25300A1/es not_active Application Discontinuation
- 1998-12-15 MA MA25396A patent/MA26586A1/fr unknown
- 1998-12-15 TN TNTNSN98227A patent/TNSN98227A1/fr unknown
- 1998-12-15 AR ARP980106360A patent/AR016433A1/es unknown
- 1998-12-15 DZ DZ980285A patent/DZ2675A1/xx active
- 1998-12-15 ZA ZA9811507A patent/ZA9811507B/xx unknown
-
2000
- 2000-05-19 IS IS5504A patent/IS5504A/is unknown
- 2000-06-13 BG BG104528A patent/BG104528A/xx unknown
- 2000-06-15 NO NO20003065A patent/NO20003065L/no not_active Application Discontinuation
- 2000-06-15 OA OA1200000169A patent/OA11423A/en unknown
- 2000-06-16 HR HR20000407A patent/HRP20000407A2/hr not_active Application Discontinuation
-
2007
- 2007-08-20 JP JP2007213745A patent/JP2007332156A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20000011A1 (es) | Combinacion eficaz para el tratamiento de la impotencia | |
PE20020469A1 (es) | Policiclicos nucleotidicos como inhibidores de xantina fosfodiesterasa v | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
PE20020228A1 (es) | Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa | |
PE20030808A1 (es) | Derivados triciclicos heterociclicos como antagonistas receptores de trombina | |
PE20011166A1 (es) | Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina | |
PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
PE20050013A1 (es) | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c | |
PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
PE20040840A1 (es) | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih | |
GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
AR054438A1 (es) | Inhibidores de adn -pk | |
PE20040832A1 (es) | Derivados de indolil pirazinona | |
PE20010736A1 (es) | PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA | |
PE20060737A1 (es) | 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
PE20020366A1 (es) | Derivados de piperazina como ligandos del receptor 5ht2 | |
PE20060285A1 (es) | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) | |
PE20200608A1 (es) | Nuevos derivados de azaquinolina | |
PA8581401A1 (es) | Compuestos de imedazopiridina como agonistas del receptor 5-ht4 | |
PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
UY27503A1 (es) | Nuevos derivados de piperazina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |